A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

NCT07230652 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Alzheimer's Disease Psychosis

Interventions

DRUG: LY03020
DRUG: Placebo

Sponsor

Luye Pharma Group Ltd.